CellCept: profile and news

New treatment for blinding eye disease Mar 3, 2006
Now, CellCept -- a drug used to prevent organ transplant rejection -- can treat eye inflammation and get patients on lower doses of, or even off, prednisone. ... - News 14 Carolina,

Aspreva Pharmaceuticals reports 2005 fourth quarter and year end ... Feb 8, 2006
Established global presence with offices in Canada, United States and Europe - Concluded SPA for the global phase III clinical trial of CellCept in lupus ... - CNW Telbec (Communiqués de presse),

Aspreva Pharmaceuticals reports 2005 fourth quarter and year end ... Feb 8, 2006
We are proud of the relationship we have established with our partner, Roche, and together we are committed to clinically developing CellCept through to ... - PharmaLive.com (press release),

Inflammatory Eye Disease Feb 21, 2006
Now, cellcept, a drug used to prevent organ transplant rejection can treat eye inflammation and get patients on lower doses of, or even off, prednisone. ... - WTVY,

Good news for Saanich company Feb 10, 2006
Saanich-based Aspreva Pharmaceuticals Corporation has announced that the anti-rejection drug CellCept has been granted an "orphan drug" designation by the US ... - Saanich News,

Drug firm gains key foothold Feb 8, 2006
...based Aspreva Pharmaceuticals Corporation announced that the US Food and Drug Administration granted "orphan drug" designation to anti-rejection drug CellCept. ... - Oak Bay News,

Aspreva revenue rockets to $76.5m Feb 9, 2006
Under the terms of the agreement Aspreva has the rights to use the transplant drug CellCept for autoimmune disease applications. ... - Vancouver Sun (subscription),

Roche shines in its annual operations Feb 1, 2006
...demand for the division's flagship oncology portfolio, now boosted by cancer treatments Avastin and Tarceva, by strong sales of CellCept (transplantation) and ... - Swissinfo,

Share of the month Feb 10, 2006
Moreover, strong sales of CellCept, for transplantation, and Pegasys, to treat hepatitis B and C, resulted in Roche’s oncology, transplantation and virology ... - Times Online,

Florida's 'health-care hurricane' Feb 2, 2006
In Ms. Jodun's case, the deductible for her two most important drugs, the immunosuppressants Cellcept and Neoril, ate up half of her "barely $500" monthly ... - Palm Beach Post,

Roche 2005: Record Sales and Operating Profit Feb 1, 2006
...s flagship oncology portfolio, now boosted by the innovative cancer treatments Avastin and Tarceva, and by strong sales of CellCept (transplantation) and ... - PharmaLive.com (press release),

Roche FY results beat expectations, sees continued strong growth ... Jan 31, 2006
...oncology drugs like MabThera and Herceptin -- fruits of its tie-up with Genentech Inc -- as well as strong sales of transplantation drug CellCept, hepatitis B ... - Forbes

Biotech's Small Caps Have Stellar January Feb 1, 2006
Aspreva benefited from the news that it had received orphan drug status for CellCept, an anti-rejection drug used for patients receiving heart, kidney and ... - CNW Telbec (Communiqués de presse),

FDA Approvals: CellCept, Prochymal, Shiga Toxin Antibodies Jan 9, 2006
On January 3, the FDA approved orphan drug status for the immunosuppressant drug mycophenolate mofetil (CellCept, made by Aspreva Pharmaceuticals Corporation ... - Medscape (subscription)

Roche shines in its annual operations Feb 2, 2006
...demand for the division's flagship oncology portfolio, now boosted by cancer treatments Avastin and Tarceva, by strong sales of CellCept (transplantation) and ... - NZZ Online,

Roche in anti-inflammatory partnership with Amira Jan 25, 2006
...disease targets, in a deal that could build on Roche’s strong position in the inflammatory market, having established its MabThera, CellCept and Actemra ... - DrugResearcher.com,

Analysts' Actions: A Daily Roundup of Street Research Jan 24, 2006
Buy. Sees strong CellCept sales, lower expenses and additional licensing potential later in the year. Raises target price to $22. ... - TheStreet.com

Roche and Amira Pharmaceuticals Announce Innovative Alliance Model Jan 8, 2006
With its broad development pipeline and existing medicines in IAT (ie, MabThera, CellCept and Actemra), Roche has the potential to become a leading provider of ... - PR Newswire (press release),

LUPUS: A transplant rejection drug may help stem kidney disease. 11 Dec 2005
They were randomly given monthly injections of the chemotherapy drug Cytoxan (cyclophosphamide) or daily oral doses of CellCept (micophenolate mofetil). ... - Evansville Courier & Press (subscription),

New drug CellCept far more effective in treating kidney problems ... Nov 24, 2005
A new study has shown that the drug CellCept is just as good at fighting kidney complications from the debilitating disease lupus with far fewer side effects ... - News-Medical.net,

Results of Investigator Initiated Trial of CellCept in Lupus ... Nov 25, 2005
...reported that the results of Dr. Ellen M. Ginzler's investigator initiated trial (IIT) comparing orally administered mycophenolate mofetil (CellCept(R)) to ... - PR Newswire (press release),

CellCept® - Statement from Sandra Raymond, President and CEO ... Nov 25, 2005
The multi-center clinical study found that MMF, or CellCept®, was more effective than the current standard-of-treatment with intravenous cyclophosphamide, and ... - Medical News Today (press release),

Aspreva Announces Completion of Patient Enrolment in Phase III ... Nov 28, 2005
...completion of enrolment of 176 patients in the phase III clinical study to assess the safety and efficacy of mycophenolate mofetil (MMF or CellCept(R)) to ... - PR Newswire (press release),

'Breakthrough' for Lupus patients Dec 6, 2005
New research published in the New England Journal of Medicine shows the drug CellCept could be far better for patients. "The drug is easier to take. ... - WFAA (subscription),

Drug Fights Lupus-Linked Kidney Disease Nov 23, 2005
...known as lupus kidney disease. The drug is mycophenolate mofetil (MMF), marketed as CellCept by drug maker Roche. If approved by the ... - Forbes

Drug shows promise in lupus patients Nov 30, 2005
MMF, which is sold as CellCept, is a simpler treatment than conventional therapy, which consists of intravenous doses of Cytoxan, a chemotherapy agent. ... - Newsday,

Drug helps treat kidney issues in lupus patients Nov 23, 2005
Nearly a quarter of patients who took the newer drug, CellCept, saw their kidney problems go into complete remission after six months, compared with just 6 ... - MSNBC

Roche drug helps lupus-linked kidney problems Nov 23, 2005
BOSTON, Nov 23 (Reuters) - Roche's CellCept is just as good at fighting kidney complications from the debilitating disease lupus with far few side effects than ... - Reuters AlertNet,

New therapy eases lupus side effects Nov 27, 2005
Nearly a quarter of patients who took the newer drug, CellCept, saw their kidney problems go into complete remission after six months, compared with just 6% of ... - Los Angeles Times,

BioCryst Out-Licenses BCX-4208 To Roche In Potential $560M Deal Nov 30, 2005
In transplantation, it could follow a path already blazed by Roche's Cellcept (mycophenolate mofetil), which Riggs said loses patent protection in five years. ... - BioWorld Online (subscription),

Unexpected Help For People With Lupus Nov 29, 2005
It is effective, but there can be severe side effects. Dr. Ellen Ginzler decided to look for an alternative to Cytoxen and tested a drug called Cellcept. ... - WJZ,

New lupus treatment found to improve on chemotherapy Nov 24, 2005
For almost 25 percent of patients who took the newer drug, CellCept, their kidney problems went into complete remission after six months, compared with 6 ... - Boston Globe,

Steroid-Free Immunosuppression After Liver Transplant Reduces ... Nov 15, 2005
SAN FRANCISCO, CA -- November 15, 2005 -- Steroid-free immunosuppression including mycophenolate mofetil (CellCept) might reduce the risk of acute cellular ... - DG News

Study: Drug aids lupus care Nov 24, 2005
The CellCept patients also had fewer side effects. ... After six months, 23 percent of those who took CellCept had complete remission. ... - Arkansas Democrat-Gazette (subscription),

Lupus nephritis, Mycophenolate Mofetil may be more effective in ... Dec 1, 2005
In lupus patients suffering from kidney inflammation Mycophenolate Mofetil ( CellCept ) may be more effective in inducing remission than standard regimen of ... - Xagena.it,

The shorter your fuse, the higher your cholesterol Nov 25, 2005
In a small study of 140 patients, they found that a newer drug called CellCept works far better than the older treatment, cyclosphosphamide. ... - Globe and Mail,

Study: Drug Shows Promise In Lupus Patients Nov 23, 2005
...at the State University of New York Downstate Medical Center in Brooklyn found that nearly one-fourth of patients who took a new drug called CellCept saw their ... - WBAL Channel.com,

Study: Drug works better than chemo in lupus patients Nov 23, 2005
The study from the State University of New York shows that nearly a quarter of patients who took a new drug called CellCept saw their kidney problems in ... - KWQC-TV,

New Treatment for Lupus Nov 24, 2005
Doctor Ellen Ginzler decided to look for an alternative and tested a drug called Cellcept. The medication is actually used on transplant ... - WLNS,

HMO Maccabi adds lifesaving cancer drug to insurance plan Dec 7, 2005
Three others - Gemzar, Taxol and CellCept / Prograf extend and even save lives, and are slated for a small number of patients. ... - Ha'aretz (subscription),

BioCryst basks after banner week Dec 4, 2005
Analysts said Roche is seeking to add to its roster of drugs used to fight organ rejection in transplant operations since its CellCept drug will begin to lose ... - Birmingham News,

Possible Lupus Kidney Disease Treatment Nov 23, 2005
...infertility. Dr. Ginzler tested the drug CellCept and found it can treat lupus-related kidney disease without as many side effects. Some ... - KOLD-TV,

Standard of care for lupus is challenged Nov 23, 2005
Marketed as CellCept and approved by the US Food and Drug Administration for use in kidney, heart and liver organ transplant patients, MMF has been shown to ... - United Press International

New Drug for Lupus Patients Nov 25, 2005
...kidney failure. A new immune-suppression drug called CellCept holds promise for treating kidney disease in Lupus patients. The previous ... - ShortNews.com,

Medical Minute Nov 24, 2005
...complications. A new study found the drug Cellcept is more effective than standard treatments at healing the kidney problems. Patients ... - KHQA,

(PRN) - Engate Offers Reputation-Based Connection Management ... Nov 28, 2005
...[+]. (PRN) - Aspreva Announces Completion of Patient Enrolment in Phase III Clinical Trial for CellCept in Myasthenia Gravis ... [+. ... - Bolsamania.com,

Research published in the NEJM challenges 30-year-old standard of ... Nov 27, 2005
Marketed as CellCept®, which is approved by the US Food and Drug Administration (FDA) for use in kidney, heart and liver organ transplant patients, MMF has ... - Medical News Today (press release),

Drug treats lupus kidney disease Nov 28, 2005
Marketed as CellCept, which is approved by the US Food and Drug Administration (FDA) for use in kidney, heart and liver organ transplant patients, MMF has been ... - myDNA.com,

(PRN) - CHC to release Second Quarter Results Dec. 13 ... [+] Nov 25, 2005
...[+]. (PRN) - Results of Investigator Initiated Trial of CellCept in Lupus Nephritis Published in The New England Journal of Medicine ... [+. ... - Bolsamania.com,

Novartis' Certican Needs Pre-Approval Safety Study With Lower Dose ... Nov 16, 2005
San Francisco) argued against approval, noting that other therapies exist for heart transplant patients, including Roche’s CellCept (mycophenolate mofetil ... - FDA Advisory Committee

(BMS) - Apertura ligeramente alcista en Estados Unidos » Apertura ... Nov 25, 2005
...[+]. (PRN) - 2005 CPR Holiday Train on the rails to raise money, food... [+. PRN) - Results of Investigator Initiated Trial of CellCept in... [+. ... - Bolsamania.com,

ACR: Lupus Prognoses Improve With Better Use of Standard Therapies Nov 21, 2005
...and other immunosuppressive and cytotoxic drugs, such as Imuran (azathioprine), Cytoxan (cyclophosphamide), methotrexate, and Cellcept (mycophenolate mofetil). ... - MedPage Today,

Combination Mycophenolate Mofetil (CellCept) and Interferon Beta ... Oct 6, 2005
THESSALONIKI, GREECE -- October 6, 2005 -- Combination treatment with mycophenolate mofetil (MMF, CellCept) and interferon beta (INF-b, Rebif or Betaferon) has ... - DG News

Aspreva and Roche conclude Special Protocol Assessment and reach ... Sep 29, 2005
...assessment (SPA) with the Cardio-Renal Division of the US Food and Drug Administration (FDA) for the phase III clinical trial of CellCept(R) (mycophenolate ... - Canada NewsWire (press release),

Open ended immunosuppressant access Sep 28, 2005
...– New Zealand kidney and heart transplant patients will have open ended access to the immunosuppressant Cellcept®(mycophenolate mofetil) from October 1st. ... - Scoop.co.nz (press release),

HGS' Phase II Data Mixed; Lupus Effort Moves Ahead Oct 5, 2005
Hoffmann-La Roche Ltd., of Basel, Switzerland, finalized a special protocol assessment with the FDA for a Phase III study with CellCept (mycophenolate mofetil ... - BioWorld Online (subscription),

No-Transfusion Liver Graft in Surgical Tour de Force Sep 26, 2005
...steroid induction, followed by maintenance therapy with Prograf (tacrolimus) and prednisone, with or without the addition of CellCept (mycophenolate mofetil). ... - MedPage Today,